Mercks New Treatment for Glioblastoma Multiforme to Launch

Published: 14 Nov 2024

Author: Precedence Research

Share :

In 2024, it was revealed that one of the top companies for cancer treatment, Merck announced that  Pembrolizumab is under clinical development, currently in Phase II. This trial is for Recurrent Glioblastoma Multiforme. The drugs for Phase II recurrent glioblastoma multiforme have a 24% phase transition rate which indicates a benchmark, entering into Phase III. The ongoing efforts by Merck to offer treatment for different types of cancer shows the strong presence of the company in this field. 

“The global glioblastoma treatment market has seen a noticeable shift, with the demand for innovative therapies increasing due to the limitations of traditional treatments such as surgery, radiation, and chemotherapy. In fact, new therapies for GBM are receiving increased attention, with a reported 30% increase in research funding for GBM treatments over the past five years.”

According to recent studies, the number of recurrent GBM cases is on the rise, with more than 200,000 new cases of glioma diagnosed annually worldwide. Additionally, the global market for GBM treatments is projected to experience growth driven by advancements in immunotherapy, targeted therapies, and personalized medicine. Merck’s entry into the field with Pembrolizumab provides a beacon of hope, with early clinical data showing promise in extending survival and improving the quality of life for GBM patients.

The North American region has a stronghold on the glioblastoma multiforme treatment market. The initiatives taken for example, the U.S. Health Resources and Services Administration received financial support from the Government for impartial access to possibly life-saving cancer screenings. Such efforts along with rising health awareness has helped the market growth in the region. 

Glioblastoma Multiforme Treatment Market Size and Forecast

The global glioblastoma multiforme treatment market size was valued at USD 2.58 billion in 2023 and is estimated to grow from USD 2.78 billion in 2024 to USD 5.68 billion by 2033, with a CAGR of 8.23% from 2024 to 2033. The U.S. glioblastoma multiforme treatment market size was valued at USD 682.19 million in 2023.

Glioblastoma Multiforme Treatment Market Key Takeaways 

• North America led the market with the largest revenue share of 42.42% in 2023. The region’s governments efforts to improve citizen’s health has aided market growth.
• Asia- Pacific is observed to be the fastest growing in the market during the forecast period. The rising number of cases of glioblastoma multiforme and necessity for effective treatment will be major drivers.
• By treatment, the surgery segment dominated the market with 33.10% of revenue share in 2023. The tumor can be completely removed, but reoperation could be a possibility. Such factors help the segment’s growth
• By treatment, the radiation therapy segment is observed to be the fastest growing market during the forecast period. The radiation therapy after surgery helps the patient’s recovery chances which is an important aspect for this segment. 
• By drug class, the TMZ segment dominated the glioblastoma multiforme treatment market in 2023. Temozolomide (TMZ) has the approval of the FDA and has proved promising for patient’s survival.
• By end-user, the hospitals segment dominated the market with 48.16% of revenue share in 2023. The growing number of people affected and requiring surgery and chemotherapy for glioblastoma multiforme treatment is helping segment growth.
• By end-user, the clinics segment was the second largest with 30.14% of revenue share in 2023. These facilities have access to new treatment procedures as well as technologies which make them a suitable choice. 

Glioblastoma Multiforme Treatment Market Report Scope

Glioblastoma Multiforme Treatment Market Key Players

• Merck & Co., Inc.
• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
• Arbor Pharmaceuticals, LLC
• Amneal Pharmaceuticals
• Karyopharm Therapeutics, Inc.

Major Highlights from Glioblastoma Multiforme Treatment Companies

• Merck’s continuous efforts for breakthroughs in cancer treatment got fruitful results in September 2024. Avelumab is a programmed human IgG1 lambda monoclonal antibody; it is under clinical development in Phase II for the treatment for Glioblastoma Multiforme cancer. 
• Growing research into combining immunotherapy with traditional treatments like chemotherapy and radiation therapy to enhance efficacy and overcome resistance.
• A 30% rise in research funding for GBM therapies, reflecting growing recognition of the need for more effective and innovative treatments.
• In September 2024, Atezolizumab is under development, having completed Phase II trials by F. Hoffman-La-Roche, one of the leading pharmaceutical companies. This will help with recurrent cases of glioblastoma multiforme cancer. 

We’ve prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344